S 689 Massachusetts Senate · 193rd Legislature (2023-2024)

An Act relative to patient access to biomarker testing to provide appropriate therapy

This bill amends Massachusetts state law to require that the state's group insurance commission cover biomarker testing for employees and retirees. The legislation defines biomarker testing as the analysis of a patient's biological samples to identify indicators of disease or drug response and mandates coverage when such tests are supported by FDA approvals, federal Medicare decisions, or nationally recognized clinical guidelines. By establishing these specific criteria, the bill aims to ensure that insured individuals have access to necessary diagnostic tools that help doctors determine the most appropriate therapy for their conditions.
Bill status passed both 4 of 5 stages cleared
Introduction
Feb 2023
Committee Review
May 2024
Senate Passage
Mar 2024
House Passage
Feb 2023
Governor
Introduced Feb 16, 2023 Last action Jun 20, 2024
Floor votes

How they voted

This bill passed the Senate. No roll call record of that vote is available.
Full legislative history

Actions timeline

Total actions
8
Key actions
3
Committee
2
May 30, 2024
Upper · Passed
Bill reported favorably by committee and referred to the committee on Health Care Financing
upper
Mar 28, 2024
Upper · Passed
Senate concurred
upper
Feb 16, 2023
Lower · Passed
House concurred
lower
Feb 16, 2023
Committee
Referred to the committee on Financial Services
upper
1 primary · 29 co-sponsors

Sponsors